Search for a command to run...
Connexin-43 (Cx43) hemichannels have been identified as a conserved mechanism exploited by pandemic-capable viruses for immune evasion, making Cx43-targeting compounds a practical approach for predicting pandemic-risk countermeasure decisions. This study profiles five known Cx43 hemichannel blockers using two complementary platforms: the mosaeQ quantum-accelerated preclinical engine (mosaeQ.com), which computes ADME, toxicity, and PBPK parameters from molecular structure via the patent-protected NEMP (S³) quantum algorithm; and the msq deterministic quantum ontology (msq.mosaeQ.com), which cross-references those predictions against four public safety databases (FDA FAERS, NTP DrugMatrix, Open TG-GATEs, and NLM DailyMed) to generate translational concordance profiles. Together, these platforms encode each compound as normed quaternion coordinates on the unit hypersphere S³ and quantify the gap between computational prediction and real-world pharmacovigilance data. All five compounds are generic, off-patent, and under €25/gram. Three (carbenoxolone, flufenamic acid, meclofenamic acid) returned null across all concordance databases — regulatory orphans with decades of clinical use but no structured post-market safety surveillance. Two (mefloquine, quinine) are World Health Organization Essential Medicines with established safety profiles. The NEMP (S³) tissue-trap zone encoding correctly differentiates carbenoxolone (plasma-retained, published Vd 0.105 L/kg) from mefloquine (Brain Trap, published Vd 19–22 L/kg) from molecular structure alone. Mefloquine is identified as the lead candidate for a pathogen-agnostic shield based on its World Health Organization Essential Medicine status and demonstrated Cx43 IC50 of ~0.3 µM (Cruikshank et al., 2004), while carbenoxolone serves as the peripheral control, confirming that the NEMP (S³) encoding correctly assigns plasma-retained distribution to compounds that do not cross the blood-brain barrier. We propose that Cx43 hemichannel blockers be evaluated as pathogen-agnostic countermeasures, deployable at the first epidemiological signal of an outbreak for any virus with high Cx43 targeting — a host-directed alternative that does not require pathogen identification, sequencing, or vaccine development.